Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Pembrolizumab/Lenvatinib Combo Shows Positive Clinical Activity in Recurrent Pleural Mesothelioma

September 13, 2022 By Thomas Lamb

The combination of pembrolizumab (Keytruda), and lenvatinib (Lenvima) demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma (MPM), according to results from the PEMMELA study (NCT04287829) presented at the International Association for the Study of Lung Cancer 2022 World Conference.

Preliminary results indicated a median overall survival (OS) of 11.4 months (95% CI, 9.8-not reached) and a median progression-free survival (PFS) of 5.6 months (95% CI, 4.5-9.3)[TB1] . The objective response rate (ORR) was 58% and 76% of patients required dose reductions, according to investigators.

“This study met its primary end point, showing promising clinical activity of pembrolizumab plus [ Lenvima ] in patients with recurrent MPM who progressed after chemotherapy, with remarkable but no unexpected toxicity,” said Li-Anne Douma, a PhD candidate at The Netherlands Cancer Institute in Amsterdam who presented the results.

In patients with MPM, there is a large unmet need for effective second-line treatment options. The PD-1 receptor blocker, pembrolizumab, has shown a response rate up to 20% as monotherapy whereas [ Lenvima ], a multiple tyrosine kinase inhibitor with mostly vascular endothelial growth factor receptor blocking properties, has synergistic interactions with PD-1 blocking in other tumors.

Because of this, investigators sought to evaluate the clinical activity and toxicity of the 2 agents in combination as treatment for patients with recurrent MPM in the phase 2 single-arm, open-label, study.

Thirty-eight eligible patients received intravenous (IV) pembrolizumab given at a dose of 200 mg once every 3 weeks plus [ Lenvima ] at 20 mg orally once a day in patients with MPM who progressed after chemotherapy….

Overall, these data demonstrate the promising clinical activity observed with treatment consisting of pembrolizumab plus [ Lenvima ] in patients with recurrent MPM who progressed after chemotherapy.

[Read full article at original site]


 Asbestos & Mesothelioma Information

  Asbestos-Mesothelioma Case Evaluation
Free.  Confidential.  No Obligation.

Filed Under: Medicine, Mesothelioma Tagged With: Keytruda, Lenvima, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Asbestos Information Overview
  • NC Asbestos Exposure Sites
  • Asbestos Cancers / Diseases
  • Legal Compensation
  • Free Case Evaluation
  • About Our Law Firm
  • Attorney Tom Lamb
  • Recent News & Reports
  • Frequently Asked Questions
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.